Treatment of HCV with the New, Direct-Acting Antiviral Medications in HCV-Monoinfected and HIV-HCV-Coinfected Individuals from an Inner-City, Predominantly Minority Patient Population

Parvin Russell; Haeri Nami Safai; Nigar Sofia; Ona Mel A.; Reddy Madhavi

首页> 外文期刊>The American Journal of Gastroenterology >Treatment of HCV with the New, Direct-Acting Antiviral Medications in HCV-Monoinfected and HIV-HCV-Coinfected Individuals from an Inner-City, Predominantly Minority Patient Population

【24h】

Treatment of HCV with the New, Direct-Acting Antiviral Medications in HCV-Monoinfected and HIV-HCV-Coinfected Individuals from an Inner-City, Predominantly Minority Patient Population

机译：在市区内主要是少数族裔人群的HCV单感染和HIV-HCV合并感染患者中使用新的直接作用抗病毒药物治疗HCV

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The American Journal of Gastroenterology》 |2016年第1期|共2页
作者
Parvin Russell; Haeri Nami Safai; Nigar Sofia; Ona Mel A.; Reddy Madhavi;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Treatment of HCV with the New, Direct-Acting Antiviral Medications in HCV-Monoinfected and HIV-HCV-Coinfected Individuals from an Inner-City, Predominantly Minority Patient Population [J] . Parvin Russell, Haeri Nami Safai, Nigar Sofia, The American Journal of Gastroenterology . 2016,第Suppla1期

机译：在市区内主要是少数族裔人群的HCV单感染和HIV-HCV合并感染患者中使用新的直接作用抗病毒药物治疗HCV
2. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01) [J] . Ingiliz Patrick, Christensen Stefan, Kimhofer Torben, Clinical infectious diseases . 2016,第10期

机译：Sofosbuvir和Ledipasvir 8周用于治疗HCV-单蛋白和HIV-HCV-焦育中的慢性丙型肝炎病毒（HCV）感染：德国丙型肝炎COHORT（GECCO-01）的结果
3. Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals [J] . KleinM.B., RolletK.C., HullM., Antiviral therapy . 2013,第5期

机译：谁需要HCV的直接作用抗病毒药？艾滋病毒/丙肝合并感染者推进丙肝治疗面临的挑战
4. Patients with HCV/HIV Co-infection Achieving a Sustained Virological Response Following HCV Treatment with Peginterferon alfa-2a (PEGASYS) plus Ribavirin (COPEGUS) have Improved Health Related Quality of Life [C] . D.T. Dieterich, M. Rodriguez Torres, J.K. Rockstroh International AIDS Conference . 2004

机译：HCV / HIV的患者在用Peginterferon Alfa-2a（Pegasys）加上利巴韦林（Copegegs）后HCV治疗后实现持续的病毒学反应，具有改善的健康相关的生活质量
5. The Distribution of Change over Time in Metabolic, Inflammatory, and Immune Parameters in HCV-monoinfected and HIV/HCV-coinfected Patients Cured of Hepatitis C Virus by Direct-Acting Antiviral Therapy [D] . Emmanuel, Benjamin. 2018

机译：通过直接作用抗病毒治疗，在HCV-单染料和HCV / HCV / HCV-焦收的患者中的代谢，炎症和免疫参数随时间随时间的分布，通过直接作用抗病毒治疗治愈丙型肝炎病毒
6. Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers [O] . Adeel A. Butt, Uzma A. Khan, Obaid S. Shaikh, -1

机译：三级医疗转诊中心的HCV单感染和HCV / HIV合并感染患者的HCV治疗合格率
7. Measuring Adherence to Hepatitis C Direct-Acting Antiviral Medications: Using the VAS in an HCV Treatment Clinic [O] . Mary Jane Burton, Andrew C. Voluse, Amee B. Patel, 2018

机译：测量丙型肝炎直接作用抗病毒药药物的粘附：使用HCV治疗诊所中的VAS

Treatment of HCV with the New, Direct-Acting Antiviral Medications in HCV-Monoinfected and HIV-HCV-Coinfected Individuals from an Inner-City, Predominantly Minority Patient Population

著录项

相似文献

相关主题

期刊订阅